Should semen analysis become the Pap smear for men?

Unusual sperm count or motility can flag risk of diseases as well as possible fertility problems. ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­  

February 19, 2026 Check out STAT+

Sponsored By

Maria Fabrizo for STAT Should semen analysis become the Pap smear for men? Some men's health experts say yes Despite scientific skepticism of semen analysis as a biomarker for overall health, entrepreneurs see a new way to get men to visit a doctor. By Annalisa Merelli STAT+ | 5 key people to watch at HHS after Trump's shake-up Trump administration makes personnel changes in advance of midterm elections. STAT looks at five power players at the top of the HHS org chart. By Chelsea Cirruzzo STAT+ | The federal directory of doctors and hospitals is coming this year The National Provider Directory is intended to help patients find doctors and hospitals and figure out if they're in network. By Bob Herman Adobe Opinion: My biggest GLP-1 ethical problem: patients who don't want to stop I used to struggle with GLP-1 shortages. Now I'm facing the opposite problems: excess medication for some patients. By Jody Dushay STAT+ | What to expect from Gossamer Bio's late-stage lung disease study In this week's edition of "Adam's Biotech Scorecard," Adam also takes a look at ProMis Neurosciences, which is developing an Alzheimer's treatment. By Adam Feuerstein STAT+ | Hims to buy Eucalyptus as it looks to expand globally The deal, which includes $240 million upfront, was framed as one that could help Hims & Hers become a leading telehealth player globally. By Andrew Joseph JASON CONNOLLY/AFP via Getty Images Opinion: I took part in a 2012 psilocybin trial. What I'm seeing now horrifies me For-profit companies are underplaying a key component of psychedelic therapy, the human guides that manage the setting and help interpret the experience. By Erica Rex STAT+ | FDA taps AI executive to lead digital health center The Food and Drug Administration has tapped a former executive from a health artificial intelligence company to lead its digital health center. By Mario Aguilar and Lizzy Lawrence

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2026, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser